If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
At present 18 per cent of the local pharmaceutical market is under government's price control
The segment delivered strong sales growth of 20% YoY
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Domestic business was up 41.9% YoY and 27.7% QoQ
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
Subscribe To Our Newsletter & Stay Updated
